Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChiCTR2100042418Phase 4Recruiting
Phase 4, randomised, open-label trial of azacitidine and dasatinib in acute myeloid leukemia (AML) (2 arms), sponsored by The First Hospital of Lanzhou University. Primary endpoints: Overall survival and Disease-free survival. Started Dec 2020; status: recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on ChiCTR2100042418.